By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investors are suing China Medical Technologies alleging the firm engaged in actions that artificially inflated its stock in violation of US securities law.

The Beijing-based in vitro diagnostics firm has been hit with at least three class action lawsuits in the past two months, including two filed in the past week, in which plaintiffs accuse the company of making false and/or misleading statements, and withholding material and adverse information.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.